Binding analysis of 95 HIV gp120 peptides to HLA-DR1101 and -DR0401 evidenced many HLA-class II binding regions on gp120 and suggested several promiscuous regions

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 14, Issue 2, 1997, Pages 91-101

  Gaudebout, P ^a   Zeliszewski, D ^a   Golvano, J J ^b   Pignal, C ^a   Le Gac, S ^a   Borras Cuesta, F ^b   Sterkers, G ^a  

^a HÔPITAL ROBERT DEBRÉ   (France)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

DR binding regions; HIV 1 gp120; Synthetic peptide; T helper determinant

Indexed keywords

GLYCOPROTEIN GP 120; HLA ANTIGEN CLASS 2; HLA DR ANTIGEN;

AMINO ACID SEQUENCE; ANTIBODY COMBINING SITE; ANTIGEN BINDING; ANTIGEN SPECIFICITY; ARTICLE; EPITOPE MAPPING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN PROTEIN INTERACTION; RADIOASSAY;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0031041759     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199702010-00001     Document Type: Article

References (37)

1. Keene JA, Forman J. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 1982;155:768-79.
2. Shirai M, Pendleton CD, Ahlers J, Takeshita T, Newman M, Berzofsky JA. Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs J Immunol 1994;152:549-56.
3. Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 1991;9:527-65.
4. Busch R, Strang G, Howland K, Rothbard JB. Degenerate binding of immunogenic peptides to HLA-DR proteins on B cell surfaces. Int Immunol 1990;2:443-8.
5. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells. Eur J Immunol 1989;19:2237-42.
6. Sinigaglia F, Guttinger M, Kilgus J, et al. A malaria T-cell epitope recognized in association with most mouse and human MHC class II molecules. Nature 1988;336:778-80.
7. Schaeffer EB, Sette A, Johnson DL, et al. Relative contribution of "determinant selection" and "holes in the T-cell repertoire" to T-cell responses. Proc Natl Acad Sci U S A 1989;86:4649-53.
8. Adorini L, Appella E, Doria G, Nagy ZA. Mechanisms influencing the immunodominance of T cell determinants. J Exp Med 1988;168:2091-4.
9. Sette A, Vitiello A, Reherman B, et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol 1994;153:5586-92.
10. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of Major Histocompatibility Complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by non dominant anchor residues. J Exp Med 1994;180:1471-83.
11. Tieber VL, Abruzzini LF, Didier DK, Schwartz BD, Rotwein P. Complete characterization and sequence of an HLA class II DR beta chain cDNA from the DR5 haplotype. J. Biol Chem 1986;261:2738-42.
12. Bell JI, Denney D Jr, Foster L, Belt T, Todd JA, McDevitt HO. Allelic variation in the DR subregion of the human major histocompatibility complex. Proc Natl Acad Sci U S A 1987;84:6234-8.
13. Zeliszewski D, Gaudebout P, Golvano JJ, et al. Molecular basis for degenerate T-cell recognition of one peptide in the context of several DR molecules. Hum Immunol 1994;41:28-33.
14. O'Sullivan D, Sidney J, del Guercio M-F, Colon SM, Sette A. Truncation analysis of several DR binding epitopes. J. Immunol 1991;146:1240-6.
15. Rothbard JB, Busch R, Bal V, Trowsdale J, Lechler RI, Lamb JR. Reversal of HLA restriction by a point mutation in a0n antigenic peptide. Int Immunol 1989;1:487-95.
16. Borras-Cuesta F, Golvano J, Sarobe P, et al. Insights on the amino acid side-chain interactions of a synthetic T cell determinant. Biologicals 1991;19:187-90.
17. Merrifield RB. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. J Am Chem Soc 1963;85:2149-54.
18. Myers G, Korber B, Berzofsky JA, Smith RF, Pavlakis GN, eds. Human retroviruses and AIDS 1993. A compilation and analysis of nucleic acid and amino acid sequences. Los Alamos, California: Los Alamos National Laboratory, 1993.
19. Benichou B, Strominger JL. Class II-antigen-negative patient and mutant B-cell lines represent at least three, and probably four, distinct genetic defects defined by complementation analysis. Proc Natl Acad Sci USA 1991;88:4285-8.
20. Snedecor GW, Cochran WG. In: Analysis of covariance in statistical methods. 8th ed. Ames, Iowa: Iowa State University Press. 1989:374-93.
21. Marshall KW, Liu AF, Canales J, et al. Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands. J. Immunol 1994;152:4946-57.
22. Choppin J, Martinon F, Connan F, Pauchard M. Gomard E, Levy JP. HLA binding regions of HIV-1 proteins. II. A systematic study of viral proteins. J Immunol 1991;147:575-83.
23. Stern LJ, Brown JH, Jardetzky TS, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature 1994;368:215-21.
24. Ghosh P, Amaya M, Mellins E, Wiley DC. The structure of an intermediate in class II MHC maturation: CLIP bound to HLA-DR3. Nature 1995;378:457-62.
25. Brown JH, Jardetzky TS, Gorga JC, et al. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993;364:33-9.
26. Jardetzky, Brown JH, Gorga JC, et al. Three-dimensional structure of a human class II histocompatibility molecule complexed with superantigen. Nature 1994;368:711-18.
27. Sette A, Sidney J, Oseroff C, et al. HLA DR4Dw4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol 1993;151:3163-70.
28. Hammer J, Valsasnini P, Tolba K, et al. Promiscuous and allele-specific anchors in HLA-DR-binding peptides. Cell 1993;74:197-03.
29. Chicz RM, Urban RG, Gorga JC, et al. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J Exp Med 1993;178:27-47.
30. O'Sullivan D, Sidney J, Appelle E, et al. Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol 1990;145:1799-808.
31. Marshall KW, Liu A, Canales J, et al. Role of the polymorphic residues in HLA-DR molecules in allele specific binding of peptide ligands. J Immunol 1994;152:4946-57.
32. Geluk A, Janson AAM, Wouter Drijfhout J, Meloen RH, De Vries RRP, Ottenkoff THM. Functional analysis of DR17 (DR3)-restricted mycobacterial T cell epitopes reveals DR17-binding motif and enables the design of allele-specific competitor peptides. J Immunol 1992;149:2864-71.
33. Sidney J, Oseroff C, Southwood S, et al. DRB1*0301 molecules recognize a structural motif distinct from one recognized by most DRB1 alleles. J Immunol 1992;149:2634-40.
34. Berzofsky JA, Pendleton CD, Clerici M, et al. Construction of peptides encompassing multideterminant clusters of HIV envelope to induce in vitro T-cell responses in mice and humans of multiple MHC types. J Clin Invest 1991;88:876-80.
35. Schrier RD, Gnann JW Jr, Landes R, et al. T cell recognition of HIV synthetic peptides in a natural infection. J Immunol 1989;142:1166-76.
36. Clerici M, Stocks NI, Zajac RA, et al. Interleukin-2 production used to detect antigen peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals Nature 1989;339:383-5.
37. Wahren B, Rosen J, Sandstrom E, Mathiesen T, Modrow S, Wigzell H. HIV-1 peptides induce a proliferative response in lymphocytes from infected persons, J Acquir Immune Defic Syndr 1989;4:448-56.